APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTIs for Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DTIs for Injection Market Outlook and Growth Opportunities 2026

29 December 2025207 pages

Choose your research edition.

Industry ResearchDTIs for Injection Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal DTIs for Injection Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal DTIs for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTIs for Injection Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal DTIs for Injection Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global DTIs for Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DTIs for Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DTIs for Injection market include Yangtze River Pharmaceutical, Beijing SL Pharmaceutical, CSPC Ouyi Pharmaceutical, Lunan Pharmaceutical, BrightGene, The Medicines Company, Teva Pharmaceutical, Sandoz and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DTIs for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DTIs for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DTIs for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DTIs for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

DTIs for Injection Segment by Company

Yangtze River Pharmaceutical

Beijing SL Pharmaceutical

CSPC Ouyi Pharmaceutical

Lunan Pharmaceutical

BrightGene

The Medicines Company

Teva Pharmaceutical

Sandoz

Pfizer

Mitsubishi Tanabe Pharma

GlaxoSmithKline

Eugia Pharma

Dr.Reddy's Laboratories

Aurobindo Pharma

Apotex

Accord Healthcare

DTIs for Injection Segment by Type

Argatroban

Bivalirudin

Other

DTIs for Injection Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

DTIs for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global DTIs for Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DTIs for Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DTIs for Injection significant trends, drivers, influence factors in global and regions.

6. To analyze DTIs for Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTIs for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTIs for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTIs for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTIs for Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DTIs for Injection industry.

Chapter 3: Detailed analysis of DTIs for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DTIs for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DTIs for Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DTIs for Injection Industry Trends Table 2. DTIs for Injection Industry Drivers Table 3. DTIs for Injection Industry Opportunities and Challenges Table 4. DTIs for Injection Industry Restraints Table 5. Global DTIs for Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DTIs for Injection Revenue Share by Company (2021-2026) Table 7. Global DTIs for Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global DTIs for Injection Sales Volume Share by Company (2021-2026) Table 9. Global DTIs for Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global DTIs for Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global DTIs for Injection Key Company Manufacturing Base & Headquarters Table 12. Global DTIs for Injection Company, Product Type & Application Table 13. Global DTIs for Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DTIs for Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Argatroban Table 18. Significant Companies of Bivalirudin Table 19. Significant Companies of Other Table 20. Global DTIs for Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global DTIs for Injection Sales Volume by Type (2021-2026) & (K Units) Table 22. Global DTIs for Injection Sales Volume by Type (2027-2032) & (K Units) Table 23. Global DTIs for Injection Sales Volume Share by Type (2021-2026) Table 24. Global DTIs for Injection Sales Volume Share by Type (2027-2032) Table 25. Global DTIs for Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global DTIs for Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global DTIs for Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global DTIs for Injection Sales Value Share by Type (2021-2026) Table 29. Global DTIs for Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Pulmonary Embolism Table 31. Significant Companies of Deep Vein Thrombosis Table 32. Significant Companies of Atrial Fibrillation Table 33. Significant Companies of Other Table 34. Global DTIs for Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global DTIs for Injection Sales Volume by Application (2021-2026) & (K Units) Table 36. Global DTIs for Injection Sales Volume by Application (2027-2032) & (K Units) Table 37. Global DTIs for Injection Sales Volume Share by Application (2021-2026) Table 38. Global DTIs for Injection Sales Volume Share by Application (2027-2032) Table 39. Global DTIs for Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global DTIs for Injection Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global DTIs for Injection Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global DTIs for Injection Sales Value Share by Application (2021-2026) Table 43. Global DTIs for Injection Sales Value Share by Application (2027-2032) Table 44. Global DTIs for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global DTIs for Injection Sales by Region (2021-2026) & (K Units) Table 46. Global DTIs for Injection Sales Market Share by Region (2021-2026) Table 47. Global DTIs for Injection Sales by Region (2027-2032) & (K Units) Table 48. Global DTIs for Injection Sales Market Share by Region (2027-2032) Table 49. Global DTIs for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global DTIs for Injection Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global DTIs for Injection Sales Value Share by Region (2021-2026) Table 52. Global DTIs for Injection Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global DTIs for Injection Sales Value Share by Region (2027-2032) Table 54. Global DTIs for Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global DTIs for Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global DTIs for Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global DTIs for Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global DTIs for Injection Sales by Country (2021-2026) & (K Units) Table 59. Global DTIs for Injection Sales Market Share by Country (2021-2026) Table 60. Global DTIs for Injection Sales by Country (2027-2032) & (K Units) Table 61. Global DTIs for Injection Sales Market Share by Country (2027-2032) Table 62. Global DTIs for Injection Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global DTIs for Injection Sales Value Market Share by Country (2021-2026) Table 64. Global DTIs for Injection Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global DTIs for Injection Sales Value Market Share by Country (2027-2032) Table 66. Yangtze River Pharmaceutical Company Information Table 67. Yangtze River Pharmaceutical Business Overview Table 68. Yangtze River Pharmaceutical DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Yangtze River Pharmaceutical DTIs for Injection Product Portfolio Table 70. Yangtze River Pharmaceutical Recent Development Table 71. Beijing SL Pharmaceutical Company Information Table 72. Beijing SL Pharmaceutical Business Overview Table 73. Beijing SL Pharmaceutical DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Beijing SL Pharmaceutical DTIs for Injection Product Portfolio Table 75. Beijing SL Pharmaceutical Recent Development Table 76. CSPC Ouyi Pharmaceutical Company Information Table 77. CSPC Ouyi Pharmaceutical Business Overview Table 78. CSPC Ouyi Pharmaceutical DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CSPC Ouyi Pharmaceutical DTIs for Injection Product Portfolio Table 80. CSPC Ouyi Pharmaceutical Recent Development Table 81. Lunan Pharmaceutical Company Information Table 82. Lunan Pharmaceutical Business Overview Table 83. Lunan Pharmaceutical DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Lunan Pharmaceutical DTIs for Injection Product Portfolio Table 85. Lunan Pharmaceutical Recent Development Table 86. BrightGene Company Information Table 87. BrightGene Business Overview Table 88. BrightGene DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. BrightGene DTIs for Injection Product Portfolio Table 90. BrightGene Recent Development Table 91. The Medicines Company Company Information Table 92. The Medicines Company Business Overview Table 93. The Medicines Company DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. The Medicines Company DTIs for Injection Product Portfolio Table 95. The Medicines Company Recent Development Table 96. Teva Pharmaceutical Company Information Table 97. Teva Pharmaceutical Business Overview Table 98. Teva Pharmaceutical DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Teva Pharmaceutical DTIs for Injection Product Portfolio Table 100. Teva Pharmaceutical Recent Development Table 101. Sandoz Company Information Table 102. Sandoz Business Overview Table 103. Sandoz DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sandoz DTIs for Injection Product Portfolio Table 105. Sandoz Recent Development Table 106. Pfizer Company Information Table 107. Pfizer Business Overview Table 108. Pfizer DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Pfizer DTIs for Injection Product Portfolio Table 110. Pfizer Recent Development Table 111. Mitsubishi Tanabe Pharma Company Information Table 112. Mitsubishi Tanabe Pharma Business Overview Table 113. Mitsubishi Tanabe Pharma DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Mitsubishi Tanabe Pharma DTIs for Injection Product Portfolio Table 115. Mitsubishi Tanabe Pharma Recent Development Table 116. GlaxoSmithKline Company Information Table 117. GlaxoSmithKline Business Overview Table 118. GlaxoSmithKline DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. GlaxoSmithKline DTIs for Injection Product Portfolio Table 120. GlaxoSmithKline Recent Development Table 121. Eugia Pharma Company Information Table 122. Eugia Pharma Business Overview Table 123. Eugia Pharma DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Eugia Pharma DTIs for Injection Product Portfolio Table 125. Eugia Pharma Recent Development Table 126. Dr.Reddy's Laboratories Company Information Table 127. Dr.Reddy's Laboratories Business Overview Table 128. Dr.Reddy's Laboratories DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Dr.Reddy's Laboratories DTIs for Injection Product Portfolio Table 130. Dr.Reddy's Laboratories Recent Development Table 131. Aurobindo Pharma Company Information Table 132. Aurobindo Pharma Business Overview Table 133. Aurobindo Pharma DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Aurobindo Pharma DTIs for Injection Product Portfolio Table 135. Aurobindo Pharma Recent Development Table 136. Apotex Company Information Table 137. Apotex Business Overview Table 138. Apotex DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Apotex DTIs for Injection Product Portfolio Table 140. Apotex Recent Development Table 141. Accord Healthcare Company Information Table 142. Accord Healthcare Business Overview Table 143. Accord Healthcare DTIs for Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Accord Healthcare DTIs for Injection Product Portfolio Table 145. Accord Healthcare Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. DTIs for Injection Distributors List Table 149. DTIs for Injection Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. DTIs for Injection Product Image Figure 2. Global DTIs for Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global DTIs for Injection Sales (2021-2032) & (K Units) Figure 5. Global DTIs for Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global DTIs for Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Argatroban Image Figure 10. Bivalirudin Image Figure 11. Other Image Figure 12. Global DTIs for Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global DTIs for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global DTIs for Injection Sales Volume Share by Type (2021-2032) Figure 15. Global DTIs for Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global DTIs for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global DTIs for Injection Sales Value Share by Type (2021-2032) Figure 18. Pulmonary Embolism Image Figure 19. Deep Vein Thrombosis Image Figure 20. Atrial Fibrillation Image Figure 21. Other Image Figure 22. Global DTIs for Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global DTIs for Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global DTIs for Injection Sales Volume Share by Application (2021-2032) Figure 25. Global DTIs for Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global DTIs for Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global DTIs for Injection Sales Value Share by Application (2021-2032) Figure 28. Global DTIs for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global DTIs for Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global DTIs for Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global DTIs for Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 33. North America DTIs for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Europe DTIs for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific DTIs for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 39. South America DTIs for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa DTIs for Injection Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa DTIs for Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt DTIs for Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt DTIs for Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt DTIs for Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. DTIs for Injection Value Chain Figure 127. Manufacturing Cost Structure Figure 128. DTIs for Injection Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Argatroban
  • Bivalirudin
  • Other
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Yangtze River Pharmaceutical
  • Beijing SL Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Lunan Pharmaceutical
  • BrightGene
  • The Medicines Company
  • Teva Pharmaceutical
  • Sandoz
  • Pfizer
  • Mitsubishi Tanabe Pharma
  • GlaxoSmithKline
  • Eugia Pharma
  • Dr.Reddy's Laboratories
  • Aurobindo Pharma
  • Apotex
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DTIs for Injection Sales Value (2021-2032)
  4. 1.2.2 Global DTIs for Injection Sales Volume (2021-2032)
  5. 1.2.3 Global DTIs for Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DTIs for Injection Market Dynamics
  1. 2.1 DTIs for Injection Industry Trends
  2. 2.2 DTIs for Injection Industry Drivers
  3. 2.3 DTIs for Injection Industry Opportunities and Challenges
  4. 2.4 DTIs for Injection Industry Restraints
3 DTIs for Injection Market by Company
  1. 3.1 Global DTIs for Injection Company Revenue Ranking in 2025
  2. 3.2 Global DTIs for Injection Revenue by Company (2021-2026)
  3. 3.3 Global DTIs for Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global DTIs for Injection Average Price by Company (2021-2026)
  5. 3.5 Global DTIs for Injection Company Ranking (2024-2026)
  6. 3.6 Global DTIs for Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global DTIs for Injection Company Product Type and Application
  8. 3.8 Global DTIs for Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DTIs for Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DTIs for Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DTIs for Injection Market by Type
  1. 4.1 DTIs for Injection Type Introduction
  2. 4.1.1 Argatroban
  3. 4.1.2 Bivalirudin
  4. 4.1.3 Other
  5. 4.2 Global DTIs for Injection Sales Volume by Type
  6. 4.2.1 Global DTIs for Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global DTIs for Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global DTIs for Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global DTIs for Injection Sales Value by Type
  10. 4.3.1 Global DTIs for Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global DTIs for Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global DTIs for Injection Sales Value Share by Type (2021-2032)
5 DTIs for Injection Market by Application
  1. 5.1 DTIs for Injection Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global DTIs for Injection Sales Volume by Application
  7. 5.2.1 Global DTIs for Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global DTIs for Injection Sales Volume by Application (2021-2032)
  9. 5.2.3 Global DTIs for Injection Sales Volume Share by Application (2021-2032)
  10. 5.3 Global DTIs for Injection Sales Value by Application
  11. 5.3.1 Global DTIs for Injection Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global DTIs for Injection Sales Value by Application (2021-2032)
  13. 5.3.3 Global DTIs for Injection Sales Value Share by Application (2021-2032)
6 DTIs for Injection Regional Sales and Value Analysis
  1. 6.1 Global DTIs for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DTIs for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global DTIs for Injection Sales by Region: 2021-2026
  4. 6.2.2 Global DTIs for Injection Sales by Region (2027-2032)
  5. 6.3 Global DTIs for Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DTIs for Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global DTIs for Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global DTIs for Injection Sales Value by Region (2027-2032)
  9. 6.5 Global DTIs for Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DTIs for Injection Sales Value (2021-2032)
  12. 6.6.2 North America DTIs for Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DTIs for Injection Sales Value (2021-2032)
  15. 6.7.2 Europe DTIs for Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DTIs for Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DTIs for Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DTIs for Injection Sales Value (2021-2032)
  21. 6.9.2 South America DTIs for Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DTIs for Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DTIs for Injection Sales Value Share by Country, 2025 VS 2032
7 DTIs for Injection Country-level Sales and Value Analysis
  1. 7.1 Global DTIs for Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DTIs for Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DTIs for Injection Sales by Country (2021-2032)
  4. 7.3.1 Global DTIs for Injection Sales by Country (2021-2026)
  5. 7.3.2 Global DTIs for Injection Sales by Country (2027-2032)
  6. 7.4 Global DTIs for Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global DTIs for Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global DTIs for Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DTIs for Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DTIs for Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DTIs for Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DTIs for Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DTIs for Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DTIs for Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DTIs for Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DTIs for Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DTIs for Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DTIs for Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DTIs for Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DTIs for Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DTIs for Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DTIs for Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DTIs for Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DTIs for Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DTIs for Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DTIs for Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DTIs for Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DTIs for Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DTIs for Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DTIs for Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DTIs for Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DTIs for Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DTIs for Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DTIs for Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DTIs for Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DTIs for Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DTIs for Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DTIs for Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DTIs for Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yangtze River Pharmaceutical
  2. 8.1.1 Yangtze River Pharmaceutical Company Information
  3. 8.1.2 Yangtze River Pharmaceutical Business Overview
  4. 8.1.3 Yangtze River Pharmaceutical DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yangtze River Pharmaceutical DTIs for Injection Product Portfolio
  6. 8.1.5 Yangtze River Pharmaceutical Recent Developments
  7. 8.2 Beijing SL Pharmaceutical
  8. 8.2.1 Beijing SL Pharmaceutical Company Information
  9. 8.2.2 Beijing SL Pharmaceutical Business Overview
  10. 8.2.3 Beijing SL Pharmaceutical DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beijing SL Pharmaceutical DTIs for Injection Product Portfolio
  12. 8.2.5 Beijing SL Pharmaceutical Recent Developments
  13. 8.3 CSPC Ouyi Pharmaceutical
  14. 8.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 8.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 8.3.3 CSPC Ouyi Pharmaceutical DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Ouyi Pharmaceutical DTIs for Injection Product Portfolio
  18. 8.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 8.4 Lunan Pharmaceutical
  20. 8.4.1 Lunan Pharmaceutical Company Information
  21. 8.4.2 Lunan Pharmaceutical Business Overview
  22. 8.4.3 Lunan Pharmaceutical DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Lunan Pharmaceutical DTIs for Injection Product Portfolio
  24. 8.4.5 Lunan Pharmaceutical Recent Developments
  25. 8.5 BrightGene
  26. 8.5.1 BrightGene Company Information
  27. 8.5.2 BrightGene Business Overview
  28. 8.5.3 BrightGene DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BrightGene DTIs for Injection Product Portfolio
  30. 8.5.5 BrightGene Recent Developments
  31. 8.6 The Medicines Company
  32. 8.6.1 The Medicines Company Company Information
  33. 8.6.2 The Medicines Company Business Overview
  34. 8.6.3 The Medicines Company DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 The Medicines Company DTIs for Injection Product Portfolio
  36. 8.6.5 The Medicines Company Recent Developments
  37. 8.7 Teva Pharmaceutical
  38. 8.7.1 Teva Pharmaceutical Company Information
  39. 8.7.2 Teva Pharmaceutical Business Overview
  40. 8.7.3 Teva Pharmaceutical DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical DTIs for Injection Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Recent Developments
  43. 8.8 Sandoz
  44. 8.8.1 Sandoz Company Information
  45. 8.8.2 Sandoz Business Overview
  46. 8.8.3 Sandoz DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sandoz DTIs for Injection Product Portfolio
  48. 8.8.5 Sandoz Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer DTIs for Injection Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Mitsubishi Tanabe Pharma
  56. 8.10.1 Mitsubishi Tanabe Pharma Company Information
  57. 8.10.2 Mitsubishi Tanabe Pharma Business Overview
  58. 8.10.3 Mitsubishi Tanabe Pharma DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mitsubishi Tanabe Pharma DTIs for Injection Product Portfolio
  60. 8.10.5 Mitsubishi Tanabe Pharma Recent Developments
  61. 8.11 GlaxoSmithKline
  62. 8.11.1 GlaxoSmithKline Company Information
  63. 8.11.2 GlaxoSmithKline Business Overview
  64. 8.11.3 GlaxoSmithKline DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline DTIs for Injection Product Portfolio
  66. 8.11.5 GlaxoSmithKline Recent Developments
  67. 8.12 Eugia Pharma
  68. 8.12.1 Eugia Pharma Company Information
  69. 8.12.2 Eugia Pharma Business Overview
  70. 8.12.3 Eugia Pharma DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eugia Pharma DTIs for Injection Product Portfolio
  72. 8.12.5 Eugia Pharma Recent Developments
  73. 8.13 Dr.Reddy's Laboratories
  74. 8.13.1 Dr.Reddy's Laboratories Company Information
  75. 8.13.2 Dr.Reddy's Laboratories Business Overview
  76. 8.13.3 Dr.Reddy's Laboratories DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Dr.Reddy's Laboratories DTIs for Injection Product Portfolio
  78. 8.13.5 Dr.Reddy's Laboratories Recent Developments
  79. 8.14 Aurobindo Pharma
  80. 8.14.1 Aurobindo Pharma Company Information
  81. 8.14.2 Aurobindo Pharma Business Overview
  82. 8.14.3 Aurobindo Pharma DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Aurobindo Pharma DTIs for Injection Product Portfolio
  84. 8.14.5 Aurobindo Pharma Recent Developments
  85. 8.15 Apotex
  86. 8.15.1 Apotex Company Information
  87. 8.15.2 Apotex Business Overview
  88. 8.15.3 Apotex DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Apotex DTIs for Injection Product Portfolio
  90. 8.15.5 Apotex Recent Developments
  91. 8.16 Accord Healthcare
  92. 8.16.1 Accord Healthcare Company Information
  93. 8.16.2 Accord Healthcare Business Overview
  94. 8.16.3 Accord Healthcare DTIs for Injection Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Accord Healthcare DTIs for Injection Product Portfolio
  96. 8.16.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DTIs for Injection Value Chain Analysis
  2. 9.1.1 DTIs for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DTIs for Injection Sales Mode & Process
  6. 9.2 DTIs for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DTIs for Injection Distributors
  9. 9.2.3 DTIs for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst